Novel Treatments Recommended for Management of Atopic Dermatitis in Adults

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2025.

via HealthDay

FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was published online July 16 in the Journal of the American Academy of Dermatology.

Dawn M.R. Davis, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues updated previous guidelines issued by the American Academy of Dermatology on the management of atopic dermatitis in adults by providing evidence-based recommendations on use of topical and systemic therapies.

The authors developed four recommendations for atopic dermatitis management in adults, all strong, with a high certainty of evidence. Tapinarof cream is recommended for adults with moderate-to-severe atopic dermatitis. Roflumilast 0.15 percent cream is recommended for adults with mild-to-moderate atopic dermatitis. Lebrikizumab is recommended for moderate-to-severe atopic dermatitis, as is nemolizumab with concomitant topical therapy.

"Additional, long-term efficacy and safety data and data on patient-reported outcomes in real-world settings are needed to provide additional insights into the efficacy, effectiveness, and safety of these therapies for the management of atopic dermatitis," the authors write. "Comparative studies of these medications and available standard AD therapies would provide an understanding of the role of these therapies in the armamentarium of AD treatments."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords